CA3185054A1 - Chromanol, quinone or hydroquinone compounds for treatment of sepsis - Google Patents
Chromanol, quinone or hydroquinone compounds for treatment of sepsisInfo
- Publication number
- CA3185054A1 CA3185054A1 CA3185054A CA3185054A CA3185054A1 CA 3185054 A1 CA3185054 A1 CA 3185054A1 CA 3185054 A CA3185054 A CA 3185054A CA 3185054 A CA3185054 A CA 3185054A CA 3185054 A1 CA3185054 A1 CA 3185054A1
- Authority
- CA
- Canada
- Prior art keywords
- sul
- compound
- lps
- sepsis
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/66—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2025730A NL2025730B1 (en) | 2020-06-02 | 2020-06-02 | Compounds for treatment of sepsis |
| NL2025730 | 2020-06-02 | ||
| PCT/NL2021/050351 WO2021246868A1 (en) | 2020-06-02 | 2021-06-02 | Chromanol, quinone or hydroquinone compounds for treatment of sepsis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3185054A1 true CA3185054A1 (en) | 2021-12-09 |
Family
ID=72659292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3185054A Pending CA3185054A1 (en) | 2020-06-02 | 2021-06-02 | Chromanol, quinone or hydroquinone compounds for treatment of sepsis |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230202997A1 (https=) |
| EP (1) | EP4157261A1 (https=) |
| JP (1) | JP2023529612A (https=) |
| AU (1) | AU2021284148A1 (https=) |
| CA (1) | CA3185054A1 (https=) |
| NL (1) | NL2025730B1 (https=) |
| WO (1) | WO2021246868A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL2010010C2 (en) * | 2012-12-19 | 2014-06-23 | Sulfateq B V | Compounds for protection of cells. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6231894B1 (en) * | 1999-10-21 | 2001-05-15 | Duke University | Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase |
| WO2004045534A2 (en) * | 2002-11-15 | 2004-06-03 | Galileo Pharmaceuticals, Inc. | Chroman derivatives for the reduction of inflammation symptoms |
| KR102137450B1 (ko) | 2012-07-12 | 2020-07-27 | 콘드리온 아이피 비.브이. | 미토콘드리아 질환을 치료하기 위한 크로마닐 유도체 |
| NL2010010C2 (en) | 2012-12-19 | 2014-06-23 | Sulfateq B V | Compounds for protection of cells. |
| MX388654B (es) * | 2015-05-22 | 2025-03-20 | Sulfateq Bv | Derivados de cromano y uso de los mismos en el tratamiento de daño en un órgano diabético, tal como un riñón. |
| US10815211B2 (en) | 2015-10-08 | 2020-10-27 | Khondrion Ip B.V. | Compounds for treating mitochondrial disease |
| AU2017281744B2 (en) | 2016-06-24 | 2022-10-27 | Fundación Para La Investigación Biomédica Del Hospital Gregorio Marañón | Cilastatin for use in the treatment of sepsis |
| SG11202003743SA (en) * | 2017-11-22 | 2020-06-29 | Khondrion Ip B V | Compounds as mpges-1 inhibitors |
| FI3762018T3 (fi) | 2018-03-08 | 2024-04-22 | Am Pharma Bv | Rekombinantti alkalinen fosfataasi käytettäväksi sepsikseen liittyvän akuutin munuaisvaurion hoitamiseen |
-
2020
- 2020-06-02 NL NL2025730A patent/NL2025730B1/en active
-
2021
- 2021-06-02 EP EP21730995.4A patent/EP4157261A1/en active Pending
- 2021-06-02 US US17/928,645 patent/US20230202997A1/en active Pending
- 2021-06-02 WO PCT/NL2021/050351 patent/WO2021246868A1/en not_active Ceased
- 2021-06-02 AU AU2021284148A patent/AU2021284148A1/en active Pending
- 2021-06-02 CA CA3185054A patent/CA3185054A1/en active Pending
- 2021-06-02 JP JP2022574167A patent/JP2023529612A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NL2025730B1 (en) | 2022-01-20 |
| EP4157261A1 (en) | 2023-04-05 |
| US20230202997A1 (en) | 2023-06-29 |
| WO2021246868A1 (en) | 2021-12-09 |
| JP2023529612A (ja) | 2023-07-11 |
| AU2021284148A1 (en) | 2022-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9572787B2 (en) | Inhibition of renal fibrosis | |
| US11583535B2 (en) | Methods of treating eye diseases associated with inflammation and vascular proliferation | |
| AU2013217933B2 (en) | Methods of treating fibrosis | |
| EP1244460A1 (en) | Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase | |
| KR20220146496A (ko) | 뉴클레오티드계 화합물의 코로나 바이러스 감염증의 치료에의 사용 | |
| WO2017088775A1 (zh) | 苯磺酰胺基苯甲酰胺类化合物用于抑制肝纤维化的用途 | |
| ZA200407182B (en) | Dexanabinol and dexanabinol analogs regulate inflammation releated genes. | |
| CA3185054A1 (en) | Chromanol, quinone or hydroquinone compounds for treatment of sepsis | |
| EP4346789B1 (en) | Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis | |
| CA2962655A1 (en) | A combination of kynurenine and antigen presenting cells (apc) as therapeutics and methods for their use in immune modulation | |
| CN105560219B (zh) | 芬戈莫德或其盐在治疗囊肿性疾病中的用途 | |
| CN111329864A (zh) | 喹唑酮类化合物及其用途 | |
| JP7628237B2 (ja) | 自己免疫疾患の予防及び／又は治療のための医薬組成物 | |
| US11554123B2 (en) | Compositions and methods for reactivating latent HIV-1 infections | |
| HK40099294A (zh) | 治疗特发性肺纤维化的辣椒素衍生物 | |
| HK40007658B (en) | Methods of treating eye diseases associated with inflammation and vascular proliferation | |
| HK40007658A (en) | Methods of treating eye diseases associated with inflammation and vascular proliferation | |
| WO2007014237A2 (en) | Radioprotective agents | |
| JP2019182845A (ja) | キヌレニンアミノトランスフェラーゼ２（ｋａｔ２）阻害剤 | |
| EP3414230A1 (en) | Tetrazole derivatives as cytochrome p450 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250523 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250523 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250526 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250526 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250820 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250820 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250821 |